Source-grounded facts extracted from Lite Strategy, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lite Strategy, Inc. reported financial results for the fiscal 2026 third quarter ended March 31, 2026.
“On May 13, 2026, Lite Strategy, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended March 31, 2026.”
Lite Strategy, Inc. dismissed Deloitte & Touche LLP as its auditor.
“At the same time, the Committee dismissed Deloitte & Touche LLP (“Deloitte”) as independent registered public accounting firm of the Company effective December 2, 2025.”
Lite Strategy, Inc. engaged CBIZ CPAs P.C. as its auditor.
“(the “Company”) undertook a selection process to determine the Company’s independent registered public accounting firm for the current fiscal year ending June 30, 2026. On December 2, 2025, the Committee approved the engagement of CBIZ CPAs P.C. (“CBIZ CPAs”) as its independent registered public accounting firm for the fiscal year ending June 30, 2026.”
Lite Strategy, Inc.: Changed corporate name from MEI Pharma, Inc. to Lite Strategy, Inc (effective 2025-09-10).
“Effective September 10, 2025, MEI Pharma, Inc. (the “Company”) changed its name to Lite Strategy, Inc. pursuant to an amendment to its amended and restated certificate of incorporation filed with the Secretary of State of the State of Delaware (the “Name Change”).”
Lite Strategy, Inc. incurred credit facility with BitGo Prime, LLC at loan fee...calculated on a daily basis at the annualized rate specified in each.
“The Agreement creates a framework under which the Company may borrow any digital assets or cash from Lender from time to time. Each loan is documented in a separate loan request agreed to by the parties setting forth the specific terms, including principal amount, fees, collateral requirements, and the date on which the loan is to commence and mature.”
Lite Strategy, Inc. completed a disposition involving Aardvark Therapeutics, Inc. for $500,000 in cash plus the Reimbursement Amount and up to $62 million in Milestone Payments (closed 2024-10-22).
“including relevant intellectual property rights, technology and contracts. Pursuant to the Asset Purchase Agreement, the Purchaser paid the Company an initial payment of $500,000 in cash plus the Reimbursement Amount (as defined in the Asset Purchase Agreement) at the closing of the transactions contemplated by the Asset Purchase Agreement (the “Closing”)”
Richard G. Ghalie departed as Chief Medical Officer at Lite Strategy, Inc..
“David M. Urso, the Company’s President and Chief Executive Officer, and Richard G. Ghalie, M.D., its Chief Medical Officer, will be leaving the Company effective August 1, 2024.”
David M. Urso departed as President and Chief Executive Officer at Lite Strategy, Inc..
“David M. Urso, the Company’s President and Chief Executive Officer, and Richard G. Ghalie, M.D., its Chief Medical Officer, will be leaving the Company effective August 1, 2024.”
Lite Strategy, Inc. announced a restructuring with charges of approximately $5.8 million affecting the Company (reduction-in-force).
“the Company expects to incur personnel-related restructuring charges of approximately $5.8 million in connection with one-time employee termination costs, including severance and other benefits, which are expected to be recognized in the first quarter of fiscal 2025”
Frederick W. Driscoll was appointed as Chairperson of the Company at Lite Strategy, Inc..
“The Board has appointed Frederick W. Driscoll as Chairperson of the Company.”
Charles V. Baltic III departed as Chairperson of the Board at Lite Strategy, Inc..
“Charles V. Baltic III, the current Chairperson of the Board, will also step down from the Board effective immediately.”
Justin J. File was appointed as Acting Chief Executive Officer at Lite Strategy, Inc..
“The Board has appointed Justin J. File, age 53, currently the Company’s Chief Financial Officer and Secretary, to serve in the additional capacity of Acting Chief Executive Officer (“Acting CEO”), effective as of August 1, 2024.”
Richard G. Ghalie departed as Chief Medical Officer at Lite Strategy, Inc..
“David M. Urso, our President and Chief Executive Officer, and Richard G. Ghalie, M.D., our Chief Medical Officer, will be leaving the Company effective August 1, 2024.”
David M. Urso departed as President and Chief Executive Officer at Lite Strategy, Inc..
“David M. Urso, our President and Chief Executive Officer, and Richard G. Ghalie, M.D., our Chief Medical Officer, will be leaving the Company effective August 1, 2024.”
Lite Strategy, Inc. reported three and nine months ended March 31, 2024 results: net income As of March 31, 2024, MEI had $56.6 million in cash, cash equivalents, and short-term investments with no outstanding de.
“As of March 31, 2024, MEI had $56.6 million in cash, cash equivalents, and short-term investments with no outstanding debt.”
Lite Strategy, Inc. reported financial results for third quarter ended March 31, 2024.
“On May 9, 2024, MEI Pharma, Inc. (the “Company”) issued a press release announcing its financial results for its third quarter ended March 31, 2024.”
Lite Strategy, Inc. reported financial results for second quarter ended December 31, 2023.
“On February 13, 2024, MEI Pharma, Inc. (the “Company”) issued a press release announcing its financial results for its second quarter ended December 31, 2023.”
Lite Strategy, Inc. engaged Deloitte & Touche LLP as its auditor.
“On December 19, 2023, the Board appointed, upon the Audit Committee's recommendation, Deloitte as the Company’s new independent registered public accounting firm effective as of December 26, 2023.”
Lite Strategy, Inc. dismissed BDO USA, P.C. as its auditor.
“On December 19, 2023, the Board of Directors (the Board) of MEI Pharma, Inc. (the Company) after a recommendation by the audit committee of the Board of MEI Pharma, Inc. (the Audit Committee), approved the dismissal of BDO USA, P.C. (BDO) as the Company’s independent registered public accounting firm.”
Lite Strategy, Inc.: Amended and restated bylaws to align with DGCL, update meeting procedures, director count, removal standard, and gender-neutral terms (effective 2023-12-18).
“On December 18, 2023, the Board of Directors (the Board) of MEI Pharma, Inc. (the Company) approved the Sixth Amended and Restated Bylaws of the Company (the Sixth A&R Bylaws), effective immediately.”
Lite Strategy, Inc. shareholders approved Ratification of Appointment of BDO USA, P.C. at the 2023-12-18 meeting.
“Proposal 4. – Ratification of Appointment of BDO USA, P.C. Proposal 4 was to ratify the appointment of BDO USA, P.C., an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending June 30, 2024. The proposal was approved. For Against Abstain 4,366,180 24,327 22,731”
Lite Strategy, Inc. shareholders approved Advisory Vote on Frequency of Advisory Vote on Executive Compensation at the 2023-12-18 meeting.
“Proposal 3. – Advisory Vote on Frequency of Advisory Vote on Executive Compensation. Proposal 3 was to approve, on an advisory basis, on the frequency of the approved, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement. The proposal was approved. 1 Year 2 Years 3 Years Abstain Broker Non-Votes 2,534,092 1,870 102,716 29,535 1,745,025”
Lite Strategy, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2023-12-18 meeting.
“Proposal 2. – Advisory Vote on Executive Compensation. Proposal 2 was to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement. The proposal was approved. For Against Abstain Broker Non-Votes 2,510,335 149,459 8,419 1,745,025”
Lite Strategy, Inc. shareholders approved Election of Director at the 2023-12-18 meeting.
“Proposal 1. – Election of Director. The following individuals, who were named as nominees in the Company’s definitive proxy statement relating to the Annual Meeting, were elected by the Company’s stockholders by a plurality of votes cast to serve a three-year term on the Company’s Board of Directors which will expire at the Company’s annual meeting of stockholders for fiscal year 2027. Information on the vote relating to the director standing for election is set forth below: Nominee For Withheld Broker Non-Votes Mr. James Flynn 2,643,853 24,360 1,745,025 Mr. Taheer Datoo 2,230,727 435,794 1,746,717 Mr. Steven Wood 2,644,765 23,448 1,745,025”
Lite Strategy, Inc. reported first quarter ended September 30, 2023 results: revenue $65.3 million, net income $56.4 million, EPS $8.46 per share.
“and related costs from our fiscal year 2023 reduction in headcount, partially offset by higher external professional services and legal expenses. • MEI recognized revenue of $65.3 million for the quarter ended September 30, 2023, compared to $8.7 million for the quarter ended September 30, 2022. The increase in revenue is due to the recognition of deferred revenue”
Steven Wood was appointed as Director at Lite Strategy, Inc..
“Mr. Steven Wood, as mutually agreed upon by the Company and Anson Funds and Cable Car, has been appointed to the Board as an additional MEI stockholder representative designated by the Board.”
Taheer Datoo was appointed as Director at Lite Strategy, Inc..
“the Company has appointed two directors designated by Anson Funds and Cable Car: Mr. James Flynn and Mr. Taheer Datoo.”
James Flynn was appointed as Director at Lite Strategy, Inc..
“the Company has appointed two directors designated by Anson Funds and Cable Car: Mr. James Flynn and Mr. Taheer Datoo.”
Sujay R. Kango resigned as Director at Lite Strategy, Inc..
“Daniel P. Gold, Ph.D., Tamar D. Howson and Sujay R. Kango have tendered their resignations as directors of the Board”
Tamar D. Howson resigned as Director at Lite Strategy, Inc..
“Daniel P. Gold, Ph.D., Tamar D. Howson and Sujay R. Kango have tendered their resignations as directors of the Board”
Daniel P. Gold resigned as Director at Lite Strategy, Inc..
“Daniel P. Gold, Ph.D., Tamar D. Howson and Sujay R. Kango have tendered their resignations as directors of the Board”
Lite Strategy, Inc.: Board approved Series A Certificate of Designation setting forth rights, powers, and preferences of Series A Preferred Shares (effective 2023-10-01).
“on October 1, 2023, the Board approved the Series A Certificate of Designation. The Series A Certificate of Designation sets forth the rights, powers, and preferences of the Series A Preferred Shares.”
Lite Strategy, Inc. entered into Rights Agreement with Computershare, Inc. (effective 2023-10-01).
“On October 1, 2023, the Board of Directors (the “Board”) of MEI Pharma, Inc., a Delaware corporation (the “Company”), approved and adopted a Rights Agreement, dated as of October 1, 2023 (the “Rights Agreement”), by and between the Company and Computershare, Inc., as Rights Agent (the “Rights Agent”).”
Lite Strategy, Inc. reported financial results for fiscal year ended June 30, 2023.
“On September 26, 2023, MEI Pharma, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal year ended June 30, 2023.”
Brian G. Drazba was terminated as Chief Financial Officer at Lite Strategy, Inc..
“the Board determined that Mr. Drazba’s employment as CFO shall terminate without cause, effective as of the Transition Date”
Justin J. File was appointed as Chief Financial Officer and Corporate Secretary at Lite Strategy, Inc..
“the Board has appointed Mr. File as CFO and Corporate Secretary, effective as of August 1, 2023”
Lite Strategy, Inc. shareholders rejected Proposal to consider and vote upon the proposal to approve the adjournment of the Special Meeting, from time to time, if necessary or appropriate, including to solicit additional proxies in the event that there are insufficient votes at the time of the Special Meeting or any adjournment or postponem at the 2023-07-23 meeting.
“Proposal No. 2 – Proposal to consider and vote upon the proposal to approve the adjournment of the Special Meeting, from time to time, if necessary or appropriate, including to solicit additional proxies in the event that there are insufficient votes at the time of the Special Meeting or any adjournment or postponement thereof to approve Proposal No. 1, was as follows: For Against Abstain 1,926,950 2,014,469 36,298”
Lite Strategy, Inc. shareholders rejected Proposal to consider and vote upon the proposal to approve, for purposes of Nasdaq Listing Rule 5635(a), of the issuance of shares of MEI Common Stock to stockholders of Infinity pursuant to the terms of the Merger Agreement at the 2023-07-23 meeting.
“Proposal No. 1 – Proposal to consider and vote upon the proposal to approve, for purposes of Nasdaq Listing Rule 5635(a), of the issuance of shares of MEI Common Stock, $0.00000002 par value per share, to stockholders of Infinity pursuant to the terms of the Merger Agreement, was as follows: For Against Abstain 1,903,448 2,046,283 27,986”
Lite Strategy, Inc. terminated Original Agreement with Kyowa Kirin Co., Ltd. (effective 2023-07-14).
“On July 14, 2023, the Company and Kyowa Kirin entered into a Termination Agreement (the “Termination Agreement”) to mutually terminate the Original Agreement, effective July 14, 2023”
Brian Drazba was terminated as Chief Financial Officer at Lite Strategy, Inc..
“Brian Drazba’s employment as the CFO of the Company will terminate as of the closing date of the Merger, and in any event no later than September 1, 2023.”
Jay File was appointed as Executive Vice President of Finance at Lite Strategy, Inc..
“appointed Jay File to be Executive Vice President of Finance (“EVP Finance”) of the Company, effective as of June 12, 2023”
David M. Urso was elected as Director at Lite Strategy, Inc..
“Mr. Urso was also elected as a member of the Board, effective as of June 8, 2023”
Daniel Gold was terminated as President and Chief Executive Officer at Lite Strategy, Inc..
“terminated the employment of Daniel Gold, Ph.D., the current President and CEO, effective as of June 2, 2023”
David M. Urso was appointed as President and Chief Executive Officer at Lite Strategy, Inc..
“On May 31, 2023, the Board of Directors (the “Board”) of MEI Pharma, Inc. (the “Company”) appointed David M. Urso to be President and Chief Executive Officer (“CEO”) of the Company, effective as of June 2, 2023”
Lite Strategy, Inc. reported the quarter ended March 31, 2023 results: revenue $5.9 million, net income Net loss was $15.4 million, or $2.32 per share, EPS $2.32 per share.
“to $8.9 million for the quarter ended March 31, 2022. The decrease primarily relates to personnel costs related to the reduction in workforce. • MEI recognized revenue of $5.9 million for the quarter ended March 31, 2023, compared to $9.7 million for the quarter ended March 31, 2022. The decrease in revenue comes as a result of the discontinuation of the”
Lite Strategy, Inc.: Filed a Certificate of Amendment to implement a 1-for-20 reverse stock split of common stock, par value $0.00000002 per share (effective 2023-04-14).
“On April 14, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, to implement the 1-for-20 reverse split of its common stock (the “Reverse Stock Split”).”
Lite Strategy, Inc.: The Company adopted Fifth Amended and Restated Bylaws to address Universal Proxy Rules and update forum selection provisions (effective 2023-02-22).
“On February 22, 2023, in connection with the effectiveness of new SEC rules regarding universal proxy cards and a periodic review of the bylaws of Company, the Company’s board of directors (the “Board”) approved and adopted the Company’s fifth amended and restated bylaws (the “Fifth Amended and Restated Bylaws”), which became immediately effective.”
Lite Strategy, Inc. entered into Agreement and Plan of Merger with Infinity Pharmaceuticals, Inc. (effective 2023-02-22).
“On February 22, 2023, MEI Pharma, Inc, a Delaware corporation (the “Company”), Infinity Pharmaceuticals, Inc., a Delaware corporation (“Infinity”), and Meadow Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of the Company (“Merger Sub” each of the Company, Merger Sub and Infinity are each sometimes referred to herein as a “Party” and collectively as the “Parties”) entered into an Agreement and Plan of Merger (the “Merger Agreement”).”
Frederick W. Driscoll departed as Director at Lite Strategy, Inc..
“Tamar D. Howson, Nicholas R. Glover and Frederick W. Driscoll will resign from the Board of Directors of the Company.”
Nicholas R. Glover departed as Director at Lite Strategy, Inc..
“Tamar D. Howson, Nicholas R. Glover and Frederick W. Driscoll will resign from the Board of Directors of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.